Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PKN1 | Q16512 | 1/20 | 0.68 |
| ▸ | PKN2 | Q16513 | 1/20 | 0.68 |
| ▸ | PARP1 | P09874 | 6/20 | 0.62 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.54 |
| ▸ | HPGD | P15428 | 2/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.54 |
| ▸ | DHODH | Q02127 | 7/20 | 0.53 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.52 |
| ▸ | GAA | P10253 | 2/20 | 0.49 |
| ▸ | MGAM | O43451 | 1/20 | 0.49 |
| ▸ | SI | P14410 | 1/20 | 0.49 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.49 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.47 |
| ▸ | GLA | P06280 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27961282 | 0.86 | PKN1 (0.79) | PKN1PKN2PARP1ALDH1A1KMT2A | |
| SCHEMBL31049579 | 0.85 | PKN1 (0.73) | PKN1PKN2PARP1DHODHADORA3 | |
| SCHEMBL11744167 | 0.84 | PARP1 (0.51) | PKN1PKN2PARP1KDM4EALDH1A1 | |
| SCHEMBL10172967 | 0.83 | PKN1 (0.73) | PKN1PKN2PARP1KDM4EALDH1A1 | |
| SCHEMBL7886398 | 0.83 | PKN1 (0.73) | PKN1PKN2PARP1KDM4EALDH1A1 | |
| SCHEMBL7943515 | 0.80 | PARP1 (0.69) | PARP1KDM4EALDH1A1HPGDKMT2A | |
| SCHEMBL7941257 | 0.80 | KMT2A (0.54) | PKN1PKN2PARP1KDM4EALDH1A1 | |
| SCHEMBL7945641 | 0.79 | MGAM (0.69) | PARP1KDM4EALDH1A1HPGDKMT2A | |
| SCHEMBL8601951 | 0.78 | PKN1 (0.55) | PKN1PKN2PARP1ALDH1A1KMT2A | |
| SCHEMBL11745692 | 0.78 | CHEK2 (0.60) | KDM4EALDH1A1HPGDKMT2ACHEK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20010024833-A1 | Methods for the solid phase synthesis of combinatorial libraries of benzimidazol, benzoxazoles, benzothiazoles, and derivatives thereof | LABORDE EDGARDO (US) | 2001-09-27 | — | — | US | claimed |
| US-6251689-B1 | BINDING TO RESIN; OXIDATION | TELIK, INC. | 2001-06-26 | — | — | US | claimed |
| US-20010024833-A1 | Methods for the solid phase synthesis of combinatorial libraries of benzimidazol, benzoxazoles, benzothiazoles, and derivatives thereof | LABORDE EDGARDO (US) | 2001-09-27 | — | — | US | disclosed |
| US-6251689-B1 | BINDING TO RESIN; OXIDATION | TELIK, INC. | 2001-06-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010024833-A1 | Methods for the solid phase synthesis of combinatorial libraries of benzimidazol, benzoxazoles, benzothiazoles, and derivatives thereof | EIF2AK2, CDK15, CDK17 | PKN1 1838/4885PKN2 1069/4885PARP1 1891/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.